MICO BIOMED CO., LTD. MiCo BioMed Co., Ltd. Share Price
Equities
A214610
KR7214610008
Advanced Medical Equipment & Technology
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,426 KRW | -2.66% |
|
-10.03% | -23.00% |
| Sales 2022 | 16.11B 11.7M 934M | Sales 2023 | 5.37B 3.9M 311M | Capitalization | 80.68B 58.57M 4.68B |
|---|---|---|---|---|---|
| Net income 2022 | -38.89B -28.24M -2.26B | Net income 2023 | -25.77B -18.71M -1.49B | EV / Sales 2022 | 6.03 x |
| Net Debt 2022 | 9.29B 6.74M 539M | Net cash position 2023 | 8.98B 6.52M 521M | EV / Sales 2023 | 13.4 x |
| P/E ratio 2022 |
-2.26
x | P/E ratio 2023 |
-1.78
x | Employees | 88 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 87.65% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.66% | ||
| 1 week | -10.03% | ||
| Current month | -18.37% | ||
| 1 month | -21.69% | ||
| 3 months | -19.02% | ||
| 6 months | -54.19% | ||
| Current year | -23.00% |
1 week
1 409.00
1 516.00
1 month
1 409.001 786.00
Current year
1 409.001 921.00
1 year
1 409.006 908.46
3 years
1 409.0017 083.65
5 years
1 409.0028 250.52
10 years
1 409.0028 250.52
| Managers | Title | Age | Since |
|---|---|---|---|
Sung-Woo Kim
CEO | Chief Executive Officer | 66 | - |
Seong-Gyu Lee
DFI | Director of Finance/CFO | 59 | 30/08/17 |
Jin-Pyeong Kim
SAM | Sales & Marketing | 51 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Seon-Kyu Jeon
CHM | Chairman | 66 | 30/08/17 |
Sung-Woo Kim
CEO | Chief Executive Officer | 66 | - |
Seong-Gyu Lee
DFI | Director of Finance/CFO | 59 | 30/08/17 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 1,426 | -2.66% | 252,582 |
| 25/04/24 | 1,465 | -0.54% | 86,748 |
| 24/04/24 | 1,473 | -0.20% | 111,354 |
| 23/04/24 | 1,476 | -1.27% | 112,547 |
| 22/04/24 | 1,495 | -5.68% | 431,247 |
End-of-day quote Korea S.E., April 25, 2024
More quotes
MiCo BioMed Co Ltd, formerly MiCo NanoBioSys Co Ltd, is a Korea-based company mainly engaged in developing in vitro diagnostic (IVD) medical equipments and devices. The Company operates its business through three segments. The Molecular Diagnosis segment mainly manufactures and sells products such as nucleic acid extraction equipment, gene amplification equipment, reagents, and lab chips. The Biochemical Diagnosis segment mainly manufactures and supplies products such as complex diagnostics, anemia meters, blood glucose meters, medical devices and strips. The Immunodiagnostic Business segment mainly produces and sells immunodiagnostic devices and immunodiagnostic kits.
Calendar
09/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -23.00% | 45.13M | |
| -11.88% | 19.08B | |
| -46.21% | 2.65B | |
| +18.15% | 1.87B | |
| -3.12% | 1.61B | |
| +24.61% | 1.21B | |
| -10.69% | 1.02B | |
| -20.89% | 905M | |
| -5.23% | 716M | |
| -18.10% | 682M |
- Stock Market
- Equities
- A214610 Stock
